RxSight (RXST) Short term Debt (2022 - 2023)
RxSight's (RXST) quarterly Short term Debt came in at $5.2 million in Q2 2023, up 186.96% YoY from $1.8 million in Q2 2022, and up 186.96% on a QoQ basis from $1.8 million in Q3 2022.
RxSight (RXST) Short term Debt (2022 - 2023) Analysis & Trends
RxSight (RXST) has 2 years of Short term Debt data on file, last reported at $5.2 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn |
| 10 | RxSight | 259.94 Mn | -144.31 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 5.22 Mn |
| Sep 30, 2022 | 1.82 Mn |
| Jun 30, 2022 | 1.82 Mn |